Stockreport

SciSparc seeks FDA IND clearance for Phase IIb Tourette Syndrome treatment trial [Yahoo! Finance]

SciSparc Ltd.  (SPRC) 
PDF its Phase IIb clinical trial of its drug candidate SCI-110 to treat Tourette Syndrome (TS). On receipt of approval, the trial is set to take place at three centres: th [Read more]